Relapsing Remitting Multiple Sclerosis study: ETNATM-ProgMS
Official title ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
ClinicalTrials.gov ID: NCT06733922
What this study is testing
- What it's testing
- The study aims to find out if new eye movement tests can accurately track how the disease changes over time.
- Who it's for
- The study is looking for people in Canada who have active relapsing-remitting multiple sclerosis and are taking a specific medication called ofatumumab.
- What's involved
- Participants will use a special eye-tracking device to record their eye movements. This tool is being tested to see if it can reliably measure disease-related changes.
- Time commitment
- The source text does not specify the total duration of the study or the number of visits required.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 99
You may be able to join if
- Adult patients who are prescribed ofatumumab as part of routine clinical care as per the PM but who have not yet received their first dose.
- Patients or their legally authorized representatives who sign the Institutional Review Boards/Independent Ethics Committee (IRB/IEC)-approved...
- Patients who meet the EDSS score range of 0 up to 7 at the time of screening and enrollment for ofatumumab treatment.
- Patients with a diagnosis of active RRMS according to the 2017 Revised McDonald criteria2.
- Patients who can provide blood samples.
You likely can't join if
- Patients with primary progressive MS, secondary progressive MS without disease activity, clinically isolated syndrome, or radiologically isolated...
- Any disease or condition that could interfere with participation in the study according to the study protocol, or with the ability of the patients to...
- Pregnant or nursing (lactating) women.
- Total abstinence (when this is in line with the preferred and usual lifestyle of the participant).
- Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six...
- Male sterilization at least six months prior to enrollment. For female participants on the study, the vasectomized male partner should be the sole...
See the full eligibility criteria
Who can join
- Adult patients who are prescribed ofatumumab as part of routine clinical care as per the PM but who have not yet received their first dose.
- Patients or their legally authorized representatives who sign the Institutional Review Boards/Independent Ethics Committee (IRB/IEC)-approved informed consent form.
- Patients who meet the EDSS score range of 0 up to 7 at the time of screening and enrollment for ofatumumab treatment.
- Patients with a diagnosis of active RRMS according to the 2017 Revised McDonald criteria2.
- Patients who can provide blood samples.
- Patients who can understand written and spoken Canadian English or French.
- Patients who have sufficient corrected visual acuity to allow for accurate reading of the on-screen visual task instructions, in the judgement of the Investigator.
- Patients with a confirmed diagnosis of MS with no signs of progressive increase in physical disability independent of relapse activity within the past six months, as assessed by a physician.
What rules you out
- Patients with primary progressive MS, secondary progressive MS without disease activity, clinically isolated syndrome, or radiologically isolated syndrome.
- Any disease or condition that could interfere with participation in the study according to the study protocol, or with the ability of the patients to cooperate and comply with the study procedures.
- Pregnant or nursing (lactating) women.
- Total abstinence (when this is in line with the preferred and usual lifestyle of the participant).
- Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks prior to enrollment.
- Male sterilization at least six months prior to enrollment. For female participants on the study, the vasectomized male partner should be the sole partner for that participant
- Use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable...
- Use of barrier methods of contraception (male or female condom, occlusive cap, diaphragm or cervical/vault caps)
- In case of use of hormonal contraception women participants should have been stable on the same method for a minimum of three months before taking study treatment.
- If local regulations are more stringent than the contraception methods listed above, local regulations apply and will be described in the ICF.
- Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms).
- Patients with hypersensitivity to ofatumumab or to any ingredient in the formulation, active hepatitis B virus, progressive multifocal leukoencephalopathy (PML), severe active infections, in a severely immunocompromised...
- Patients with an active chronic disease (or stable but treated with immune therapy) of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis...
- Patients who are using other investigational drugs within 30 days prior to or at the Baseline Visit, or within a period corresponding to five elimination half-lives, whichever is longer, or who are using other...
- Contraindication or inability to undergo regular testing (e.g., MRI, blood tests) as per standard of care.
- Patients who have been treated with cladribine or with alemtuzumab at any time within the 12 months prior to the Baseline Visit.
- Patients who have had any prior exposure to anti-CD20 B-cell therapy (i.e., ocrelizumab, ofatumumab) or natalizumab.
- Medical history or evidence of health issues that, in the opinion of the Investigator, may affect movements and oculomotor control.
The study team makes the final eligibility decision.
Where it is enrolling
- Calgary, Alberta, Canada
- Edmonton, Alberta, Canada
- Burnaby, British Columbia, Canada
- Vancouver, British Columbia, Canada
- St. John's, Newfoundland and Labrador, Canada
- Halifax, Nova Scotia, Canada
- Ottawa, Ontario, Canada
- Montreal, Quebec, Canada
- Québec, Quebec, Canada
- Sherbrooke, Quebec, Canada
- Regina, Saskatchewan, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 99 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Calgary, Alberta, Canada; Edmonton, Alberta, Canada; Burnaby, British Columbia, Canada; Vancouver, British Columbia, Canada; St. John's, Newfoundland and Labrador, Canada; Halifax, Nova Scotia, Canada and 5 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.